A fruitful congress of the European Society of Medical Oncology last week provided key insights into melanoma, lung, kidney and ovarian cancer research. 19 September 2017
A view on the future of rare disease drug development and population health from Michelle Hoffman, senior vice president of strategy consulting at Boston-based 4 September 2017
A total of 32 biosimilar products, based on 12 biologics, have been approved for use in the European Union. This compares with just ten in the USA, referencing 22 August 2017
A number of questions have been bouncing around the early-stage drug discovery community for a number of years now, particularly in the UK and Europe where a pe 15 August 2017
In March 2016, Barack Obama became the first US President to visit Cuba since 1928, marking one of the final stages in a progressive thaw in relations that, it 7 August 2017
Twenty-first century data is providing the data-heavy pharma industry with a modern dilemma: how to preserve corporate information when the speed of technologic 1 August 2017
The most recent new treatment for Alzheimer’s disease was approved by European regulators in May 2002, with the US Food and Drug Administration following suit t 26 July 2017
27 years ago last January, a letter in the New England Journal of Medicine concluded that: “despite widespread use of narcotic drugs in hospitals, the developme 12 July 2017
Dr Nicola Davies looks at how real world evidence carries ever greater importance in an industry where often regulatory approval alone is no longer enough. 4 July 2017
Anyone unfamiliar with pharma might be puzzled by how often the word ‘innovation’ comes up in dialogue, campaigning and marketing messages. 24 June 2017
With so much of the exciting data at ASCO 2017 again surrounding cancer immunotherapies, The Pharma Letter finds confidence that more will follow in the footste 8 June 2017
With data so many innovative but expensive new oncology treatments being presented at ASCO 2017.it is a crucial period for biosimilars of three of the world's b 1 June 2017
In the run up to the annual meeting of the American Society of Clinical Oncology, we present the first of three analyses focusing on the state of cancer researc 23 May 2017
With a global society of researchers, regulators and clinicians celebrating its 25th anniversary, 2017 is a good time to consider how cellular therapies have pr 16 May 2017
While pharma companies pile into areas such as oncology and central nervous system disorders in the hope that they can offer the next lifesaving treatment. 9 May 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.